M. Kulyk & Associates LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

M. Kulyk & Associates LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 258.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,373 shares of the biopharmaceutical company’s stock after acquiring an additional 10,368 shares during the period. Regeneron Pharmaceuticals makes up approximately 1.6% of M. Kulyk & Associates LLC’s portfolio, making the stock its 19th largest position. M. Kulyk & Associates LLC’s holdings in Regeneron Pharmaceuticals were worth $8,082,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC increased its holdings in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $226,000. Oppenheimer Asset Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 32.7% during the second quarter. Oppenheimer Asset Management Inc. now owns 2,608 shares of the biopharmaceutical company’s stock valued at $1,369,000 after buying an additional 643 shares during the last quarter. Banco Santander S.A. increased its holdings in Regeneron Pharmaceuticals by 65.0% in the 2nd quarter. Banco Santander S.A. now owns 19,558 shares of the biopharmaceutical company’s stock worth $10,268,000 after buying an additional 7,706 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd raised its position in Regeneron Pharmaceuticals by 259.4% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 34,874 shares of the biopharmaceutical company’s stock worth $18,309,000 after buying an additional 25,170 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on REGN shares. Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Canaccord Genuity Group raised their target price on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and boosted their target price for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. Evercore increased their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday, January 22nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $793.81.

Insider Buying and Selling

In related news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the sale, the director owned 17,803 shares in the company, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 5,274 shares of company stock worth $4,142,738 over the last ninety days. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Up 0.9%

REGN opened at $787.04 on Tuesday. The firm’s 50 day simple moving average is $769.67 and its two-hundred day simple moving average is $676.28. The company has a market capitalization of $83.21 billion, a PE ratio of 18.94, a PEG ratio of 2.09 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the firm posted $12.07 EPS. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be given a $0.94 dividend. The ex-dividend date is Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.